Comparing the current results to its competitors, Vaccinex Inc reported Revenue increase in the 4 quarter 2024 by 0 % year on year. The revenue growth was below Vaccinex Inc 's competitors' average revenue growth of 15.89 %, achieved in the same quarter.
Vaccinex Inc 's Comment on Competition and Industry Peers
The current treatment landscape for Alzheimer's disease includes symptom management medications such as cholinesterase inhibitors Donepezil (Aricept®), Rivastigmine (Exelon®), Galantamine (Razadyne®), the glutamate regulator Memantine (Namenda®), and drugs addressing non-cognitive symptoms like Suvorexant (Belsomra®) and Brexpiprazole (Rexulti®). The company states it is the only one targeting SEMA4D for neurodegenerative diseases, cancer, or autoimmune disorders. If its product pepinemab is successful, it would compete with therapies employing different mechanisms of action. Competition arises from major pharmaceutical and biotechnology companies, academic institutions, governmental agencies, and research organizations. Key competitive factors include efficacy, safety, convenience, generic competition, reimbursement availability, and regulatory approval timing. Competitors may achieve faster regulatory approvals or secure intellectual property rights that could restrict the company's ability to develop or commercialize products.
May 27, 2025
In the evolving landscape of biopharmaceutical innovation, Vaccinex Inc. has emerged as a key player with its investigational drug pepinemab, a monoclonal antibody showing great potential in treating both head and neck cancer as well as Alzheimer s disease. The recent findings presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and the forthcoming updates from the Alzheimer s Association International Conference highlight the drug s ability to enhance immune responses and delay neurodegeneration, thereby underscoring its dual therapeutic utility. Promising Advances in OncologyAt the ASCO Annual Meeting, Vaccinex reported exciting new clinical results from a neoadjuvant treatment stud...
July 17, 2024
Unveiling Hope: Vaccinex to Present Promising Topline Data for Pepinemab in Alzheimer s Disease at AAIC 2024The relentless quest for a breakthrough in Alzheimer s disease (AD) treatment has led researchers down myriad pathways, each holding potential keys to a better future. Among these innovative efforts, Vaccinex, a leader in the biotechnology field, is poised to present pivotal topline data from its SIGNAL-AD Phase 1b/2 trial of Pepinemab. This momentous presentation will take place at the prestigious Alzheimer s Association International Conference (AAIC) in Philadelphia on July 31, 2024. Pepinemab: A Beacon of InnovationPepinemab is an investigational monoclonal antibody designed to address one of the ...
June 6, 2024
Patient visits conclude in Alzheimer’s disease clinical trial; Data expected to be presented in July following database lock in June. Vaccinex, Inc. recently announced a significant milestone in the fight against Alzheimer s disease with the completion of the last patient visit in the SIGNAL-AD Phase 1b/2 clinical study. This trial is focused on evaluating the safety, tolerability, and efficacy of Pepinemab, a monoclonal antibody, as a novel treatment for patients suffering from Alzheimer s disease. A Landmark in Alzheimer s Research The SIGNAL-AD study represents a promising leap in Alzheimer s research and provides hope for millions of patients and caregivers worldwide. Vaccinex s investigational treatme...
February 21, 2024
In a breakthrough announcement, Vaccinex Inc., a renowned clinical-stage biotechnology company, has unveiled multiple strategic agreements that grant access to their cutting-edge ActivMAb Antigen Virus Technology. These new agreements mark a significant development in the field of antibody discovery and demonstrate Vaccinex s commitment to advancing the discovery and development of novel therapeutics. This article aims to explore the implications of these agreements and highlight the potential impact on the medical and pharmaceutical sectors.Expanding Capabilities with the ActivMAb Drug Discovery Platform:Vaccinex has harnessed the power of its proprietary ActivMAb Drug Discovery Platform to revolutionize th...
Xencor Inc is a biotechnology company that primarily focuses on the development of therapeutic antibodies. Their business model revolves around utilizing their proprietary XmAb® technology to engineer antibodies with enhanced properties for the treatment of various diseases. They collaborate with pharmaceutical companies to develop and commercialize these antibody therapeutics, generating revenue through upfront payments, milestone payments, and royalties.
Rain Therapeutics Inc is a biopharmaceutical company that focuses on discovering and developing precision oncology therapies. Their business model revolves around identifying genetic alterations and biomarkers in cancer patients, and then developing targeted therapies to address these specific alterations. By tailoring treatments to individual patients, they aim to improve outcomes and provide more effective and personalized cancer care.
Rapt Therapeutics Inc operates based on a business model that focuses on developing and commercializing transformative oral small molecules, known as immunomodulators. Their compounds target specific immune cell subsets within the body to provide potential therapeutic benefits in various diseases. By leveraging their expertise in immunology and small molecule drug design, Rapt strives to deliver innovative treatment options to patients in need.
Regeneron Pharmaceuticals Inc operates a business model centered on the discovery and commercialization of cutting-edge biopharmaceuticals, particularly in the fields of ophthalmology, oncology, immunology, and rare diseases. They leverage their strong research and development capabilities, including their proprietary technologies, to create innovative therapies that address unmet medical needs. Additionally, Regeneron forms strategic collaborations and partnerships to enhance their development pipeline and expand market access for their products.
Repare Therapeutics Inc is a biotechnology company that specializes in the development of precision oncology drugs. Their business model focuses on leveraging synthetic lethality, a targeted therapy approach, to identify and develop small molecule drugs for the treatment of various forms of cancer. By discovering and advancing novel therapeutics, Repare Therapeutics aims to improve patient outcomes and address unmet medical needs in oncology.
Sources:
Vaccinex Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Vaccinex Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
